



Press Release



MEDTECH PROPOSES TO NOMINATE 2 NEW BOARD MEMBERS AT ITS NEXT GENERAL MEETING ON MAI 22, 2014

Montpellier, May 7, 2014 – MEDTECH (Euronext, FR0010892950 - ROSA), a company specialized in designing, developing and marketing innovative surgical robots, will propose nominating Pr. Jacques MARESCAUX and Marie-Laure GARRIGUES, representing BPIFrance, at the next Mixed General meeting to be held on May 22.

Pr. Jacques MARESCAUX is a hospital practitioner, French academician and head of the Department of Gastrointestinal and Endocrine Surgery at Strasbourg University Hospital. He is also founder of the Institute of Research against cancer of the digestive tract (Ircad), recognized worldwide as the gold standard for minimally invasive surgery, and the European Institute of TeleSurgery.

Marie-Laure GARRIGUES, pharmacist and former intern in medical biology, has been the Director of investments at CDC Entreprises since 2008. She founded Bio-Thema Consulting, and worked as a consultant in the biotechnologies sector. Moreover she was also on the Board of Directors at Faust Pharmaceuticals, BioAlliance Pharma, GeneSystems, Palumed, Fournitures Hospitalières, Proteus, Ingen Biosciences, and, in 2007 presided at Pherecydes Pharma.

Strengthening Medtech's Board of Directors with these two nominees is part of Medtech's strategic priorities. Pr. Jacques MARESCAUX's international expertise would bring a decisive contribution to the company's development. Marie-Laure GARRIGUES' presence is proof of BPIFrance's interest in innovative companies, as a supplement to their participation at the time of going public.

Coming next :

Publication of the figures for the 3rd quarter 2013/2014,

May 12, 2014 (after Stock Exchange).

About MEDTECH

MEDTECH, founded in 2002 by Bertin NAHUM and based near Montpellier, is the European specialist in design, development and marketing of innovative robotic-assistive devices for medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less invasive treatment.

In 2006, MEDTECH sold the patent portfolio for its first robot, BRIGIT™, designed for knee surgery, to Zimmer Inc. (NYSE : ZMH).

In 2007, MEDTECH developed ROSA™ Brain, an innovative robotic device devoted to brain surgery, which has now been officially approved in Europe, the United States and Canada.

With the launch of its latest robot, ROSA™ Spine, MEDTECH has broadened its field of intervention with this new equipment for spinal surgery.

In 2013, MEDTECH received the «European Company of the Year » award in the «robotics neurosurgery » category from Frost & Sullivan.



A unique integrated platform
for minimally invasive brain
and spine surgery



Press Release

CONTACT MEDTECH
Christophe Sibillin
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40

CONTACT for INVESTORS
Corinne Puissant
Tel : +33 (0)1 53 67 36 57
cpuissant@actus.fr

PRESS CONTACT
Alexandra Prisa
Tel. : +33(0)1 53 67 35 79
aprisa@actus.fr